Education
| School — Major — Degree | Duration |
|---|---|
|
國立中山大學 — 化學系(畢) — 博士 Doctorate, Department of Chemistry, National Sun Yat-sen University, Taiwan |
2006/09 — 2011/06 |
|
國立清華大學 — 生物科技研究所(畢) — 碩士 Master, Institute of Biotechnology, National Tsing Hua University, Taiwan |
2000/09 — 2002/06 |
|
國立中山大學 — 化學系(畢) — 學士 Bachelor, Department of Chemistry, National Sun Yat-sen University, Taiwan |
1996/09 — 2000/06 |
Intramural Experience
| Office/Department/Institute | Position | Duration |
|---|---|---|
| 學士後醫學系 School of Post-Baccalaureate Medicine | Professor | 2023/08/01 — |
| 學士後醫學系 School of Post-Baccalaureate Medicine | Associate Professor | 2020/08/01 — 2023/07/31 |
| 生物化學科 Department of Biochemistry | Associate Professor | 2018/08/01 — 2020/07/31 |
| 生物化學科 Department of Biochemistry | Assistant Professor | 2013/08/01 — 2018/07/31 |
Extramural Experience
| DEPNO | Position- Office/Department/Institute | Duration |
|---|---|---|
| 國家實驗研究院國家高速網路與計算中心高速計算技術與應用組 | 副研究員 | 0911014 — 1020831 |
Discipline
| NO | Discipline | Expertise |
|---|---|---|
| 1 | 生物醫農類 Biology, Medicine and Agriculture | 生物學之生化及分子生物 Biochemistry and Molecular Biology |
| 2 | 自然科學類 Natural Sciences | 化學 Chemistry |
Research & Technology Platform Open to the Outside
Interested Area(s)for Interdisciplinary Research
新藥開發、結構生物學
drug design
Area(s) of Expertise & Research
電腦輔助藥物設計、生物巨分子結構學。生物資訊、物理化學、電腦輔助藥物設計、分子動力學、量子力學、生物化學、生物巨分子結構學。
Bioinformatic、Physical Chemistry、Computer-Aided Drug Design、Molecular Dynamics、Quantum Mechanics、Biochemistry、Macromolecular。
Publication
| NO | Publication |
|---|---|
| 1 | 使用電腦計算方法研究 Caffeine穩定 Hydroxypropyl-β-cyclodextrin/Axitinib 藥物傳輸系統 Caffeine as a stabilizer in Novel Hydroxypropyl-β-cyclodextrin/Axitinib Drug-Delivery Systems: A computational study |
| 2 | RNF43 失活增強 B-RAF/MEK 信號並產生癌症細胞中的聯合治療靶標 RNF43 Inactivation Enhances the B-RAF/MEK Signaling and Creates a Combinatory Therapeutic Target in Cancer Cells |
| 3 | Selective activation of IFNγ-ipilimumab enhances the therapeutic effect and safety of ipilimumab. Selective activation of IFNγ-ipilimumab enhances the therapeutic effect and safety of ipilimumab. |
| 4 | Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection. Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection. |
| 5 | Integrating molecular dynamics simulation with small- and wide-angle X-ray scattering to unravel the flexibility, antigen-blocking, and protease-restoring functions in a hindrance-based pro-antibody. Integrating molecular dynamics simulation with small- and wide-angle X-ray scattering to unravel the flexibility, antigen-blocking, and protease-restoring functions in a hindrance-based pro-antibody. |
| 6 | In silico validation of allosteric inhibitors targeting Zika virus NS2B–NS3 protease In silico validation of allosteric inhibitors targeting Zika virus NS2B–NS3 protease |
| 7 | Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication. Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication. |
| 8 | A Low-Cost, Sensitive Reporter System Using Membrane-Tethered Horseradish Peroxidase for Efficient Gene Expression Analysis A Low-Cost, Sensitive Reporter System Using Membrane-Tethered Horseradish Peroxidase for Efficient Gene Expression Analysis |
| 9 | Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. |
| 10 | 用於奈米級液相層析之胜肽手性衍生試劑：半胱氨酸的氧化態對布洛芬手性分離的影響 Peptide-based chiral derivatizing reagents in nano-scale liquid chromatography: Effect of the oxidation state of cysteine moiety on enantioseparation of ibuprofen |
| 11 | A universal in silico V(D)J recombination strategy for developing, humanized monoclonal antibodies A universal in silico V(D)J recombination strategy for developing, humanized monoclonal antibodies |
| 12 | Structural insights into Nirmatrelvir (PF-07321332)-3C-like SARS-CoV-2 protease complexation: a ligand Gaussian accelerated molecular dynamics study. Structural insights into Nirmatrelvir (PF-07321332)-3C-like SARS-CoV-2 protease complexation: a ligand Gaussian accelerated molecular dynamics study. |
| 13 | Anti-TNF Alpha Antibody Humira with pH-dependent Binding Characteristics: A constant-pH Molecular Dynamics, Gaussian Accelerated Molecular Dynamics, and In Vitro Study. Anti-TNF Alpha Antibody Humira with pH-dependent Binding Characteristics: A constant-pH Molecular Dynamics, Gaussian Accelerated Molecular Dynamics, and In Vitro Study. |
| 14 | Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies. Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies. |
| 15 | Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice |
| 16 | Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies (Jul, 10.1039/D1SC01748A, 2021) Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies (Jul, 10.1039/D1SC01748A, 2021) |
| 17 | chtinase1198動力學研究 Gene Cloning, Characterization, and Molecular Simulations of a Novel Recombinant Chitinase from Chitinibacter Tainanensis CT01 Appropriate for Chitin Enzymatic Hydrolysis |
| 18 | 以分子模擬進行 Tsg101 UEV 蛋白與環狀胜肽抑制劑之研究 Cyclic Peptide Inhibitors of the Tsg101 UEV Protein Interactions Refined through Global Docking and Gaussian Accelerated Molecular Dynamics Simulations |
| 19 | 使用高速加速分子動力學研究MU opioid receptor構型變化 In silico studies of conformational dynamics of Mu opioid receptor performed using gaussian accelerated molecular dynamics |
| 20 | 茲卡病毒NS5蛋白與藥物抑制劑之分子模擬 A molecular dynamics simulation study decodes the Zika virus NS5 methyltransferase bound to SAH and RNA analogue |
| 21 | 熱與紫外線B對於角質細胞之影響: 紫外線B誘導之癌症新知 The effect of interaction of heat and UVB on human keratinocyte: Novel insights on UVB-induced carcinogenesis of the skin. |
| 22 | 分子動力學在嗎啡受體蛋白Mu上的研究 Understanding the molecular basis of agonist/antagonist mechanism of human mu opioid receptor through gaussian accelerated molecular dynamics method |
| 23 | PEPTIDE 接合模擬方法 A fragment-based docking simulation for investigating peptide–protein binding |
| 24 | 建構可被蛋白酶活化的選擇性抗體 Selective antibody activation through protease-activated proantibodies that mask binding sites with inhibitory domains |
| 25 | DPP4抑制劑之分子模擬 Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulatio |
| 26 | Histone methyltransferase Suv39h1 attenuates high glucose-induced fibronectin and p21WAF1 in mesangial cells. Histone methyltransferase Suv39h1 attenuates high glucose-induced fibronectin and p21WAF1 in mesangial cells. |
| 27 | 進紅外光亮子點在生物醫學影像應用 Dual Colorimetric and Fluorescent Imaging of Latent Fingerprints on Both Porous and Nonporous Surfaces with Near-Infrared Fluorescent Semiconducting Polymer Dot |
| 28 | Groes對Importance of the C-terminal histidine residues of Helicobacter pylori GroES for Toll-like receptor 4 與 interleukin-8 cytokine 結合分析 Importance of the C-terminal histidine residues of Helicobacter pylori GroES for Toll-like receptor 4 binding and interleukin-8 cytokine production |
| 29 | Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. |
| 30 | Steap4 attenuates high glucose and S100B-induced effects in mesangial cells Steap4 attenuates high glucose and S100B-induced effects in mesangial cells |
| 31 | Insight into the modified Ibalizumab-human CD4 receptor interactions: using a computational binding free energy approach. Insight into the modified Ibalizumab-human CD4 receptor interactions: using a computational binding free energy approach. |
| 32 | 電腦輔助藥物設計在NDM1上的應用 Inhibitor and Substrate Binding by New Delhi metallo-beta-lactamase-1: A Molecular Dynamics Studies |
| 33 | H7N9 neuraminidases抑制劑算計 Molecular basis of R294K mutation effects of H7N9 neuraminidases with drugs and cyclic peptides: an in silico and experimental study |
| 34 | MTTP-297H polymorphism reduced serum cholesterol but increased risk of non-alcoholic fatty liver disease-a cross-sectional study MTTP-297H polymorphism reduced serum cholesterol but increased risk of non-alcoholic fatty liver disease-a cross-sectional study |
| 35 | 混和量子力學與分子動力學對NDM1與抑制劑之研究 Refined Models of New Delhi metallo-beta-lactamase-1 with Inhibitors: An QM/MM Modeling Study |
| 36 | 金奈米線的研究 Investigation into the formation of 13-6 helical multi-shell gold nanowires |
| 37 | 使用分子模擬方法研究流感與藥物治療 Insights from QM/MM Modeling the 3D Structure of the 2009 H1N1 Influenza A Virus Neuraminidase and Its Binding Interactions with Antiviral Drugs |
| 38 | Development of an Anti-Methoxy Poly(ethylene glycol) (α-mPEG) Cell-Based Capture System to Measure mPEG and mPEGylated Molecules Development of an Anti-Methoxy Poly(ethylene glycol) (α-mPEG) Cell-Based Capture System to Measure mPEG and mPEGylated Molecules |
| 39 | 短胜肽藥物活性研究 Serendipitous Discovery of Short Peptides from Natural Products as Tyrosinase Inhibitors |
| 40 | 使用分子模擬方法研究 Ibalizuma抗體藥物 Insight into the modified Ibalizumab-human CD4 receptor interactions: using a computational binding free energy approach |
| 41 | 使用分子模擬方法研究2013年H7N9流感病毒之神經氨酸酶與藥物作用模型 Insights from modelling the 3D structure of the 2013 H7N9 influenza A virus neuraminidase and its binding interactions with drugs |
| 42 | 奈米碳管特性探討與模擬 Influence of oriented topological defects on the mechanical properties of carbon nanotube heterojunctions |
| 43 | Predictions of Binding for Dopamine D2 Receptor Antagonists by the SIE,Method Predictions of Binding for Dopamine D2 Receptor Antagonists by the SIE,Method |
Project
| NO |
YEAR — Source — No — Type
Project Name
|
Duration |
|---|---|---|
| 1 |
113 — DK 前瞻重點(原校院) — KMU-DK(B)114001-1 —
開發混合長短碳鍊mPEG-脂質(mPEG-C18/C14)之高穩定mRNA-LNP以作為標靶性mRNA-LNP( )
|
2025/01/01 ~ 2025/12/31 |
| 2 |
113 — KT 高醫清大 — KT113P004 — 1 個人型
以X光晶體繞射法及冷凍電顯探討雙價抗聚乙二醇之三功能抗體(αmPEG×αPEG×αHER2)與聚乙二醇微脂體藥物 (PLD)的結合情形(Study on the Binding of Bivalent Anti-PEG Trispecific Antibody (ɑmPEG×ɑPEG×ɑHER2) and PEGylated liposomal doxorubicin (PLD) by X-ray Crystallography and cryo-EM)
|
2024/01/01 ~ 2024/12/31 |
| 3 |
113 — N 國科會(原科技部) — NSTC113-2124-M-037-001 — 1 個人型
開發具雙價抗聚乙二醇之三功能抗體(mPEG X PEG X HER2)一步武裝聚乙二醇奈米藥物以提升其活體內結合穩定度及治療效果(3/3)( )
|
2024/08/01 ~ 2025/07/31 |
| 4 |
112 — DK 前瞻重點(原校院) — KMU-DK(A)113014 —
開發針對茲卡與登革熱毒複製之雙重靶向異位調控抑制劑的通用電腦模擬與體外活性測試策略( )
|
2024/01/01 ~ 2024/12/31 |
| 5 |
112 — KP 高醫屏科大 — NPUST-KMU-112-P006 —
使用分子模擬方法與體外活性實驗方法探究具有nirmatrelvir 抗藥性之3C-like SARS-CoV-2 Protease在結構上結合模式( )
|
2023/01/01 ~ 2023/12/31 |
| 6 |
112 — N 國科會(原科技部) — NSTC112-2113-M-037-015 — 1 個人型
使用分子模擬方法與體外活性實驗方法探究具有Nirmatrelvir, PF-00835231與GC376抗藥性之自然發生突變3C-like SARS-CoV-2 Proteases之結構上結合模式( )
|
2023/08/01 ~ 2024/09/30 |
| 7 |
111 — DK 前瞻重點(原校院) — KMU-DK(B)112002-3 — 2 整合型
以臨床檢體蛋白酶譜建立 前驅抗 hROR1 細胞療法 在三陰性乳癌患部之再活 化效率與療效評估平台( )
|
2023/01/01 ~ 2023/12/31 |
| 8 |
111 — N 國科會(原科技部) — MOST111-2113-M-037-008 — 1 個人型
使用配體高斯分子加速動力學與體外活性實驗方法探究3C-like SARS-CoV-2 Protease與具治療潛力抑制劑在結構上結合模式( )
|
2022/08/01 ~ 2023/07/31 |
| 9 |
110 — DK 前瞻重點(原校院) — KMU-DK(B)111001-1 —
以電腦結構計算優化 h15-2b (anti-甲基 PEG), h6-3 (anti-PEG 骨架)抗體的親合力以增 進雙價抗聚乙二醇三功能抗體一步武裝奈米藥物的穩定度( )
|
2022/01/01 ~ 2022/12/31 |
| 10 |
110 — NK 高醫-中山合作計畫 — — 1 個人型
結合分子模擬與實驗方法預測環糊精與藥物分子作用機制 ( )
|
2021/01/01 ~ 2021/12/31 |
| 11 |
110 — TC 研究中心計畫 — KMU-TC111A03-4 —
以電腦深度學習法客製化開發中和PD-1關鍵抗原決定位之高親和力全人類抗體藥物( )
|
2022/01/01 ~ 2022/12/31 |
| 12 |
109 — DK 前瞻重點(原校院) — KMU-DK(B)110004-1 —
以電腦模擬優化具不同蛋白酶活化特性之前驅抗體(pro-αEGFR Ab)的遮蔽率與活化效率( )
|
2021/01/01 ~ 2021/12/31 |
| 13 |
109 — KC 高醫陽明交大 — NCTUKMU109-DR-01 — 1 個人型
電腦學習模擬與體外活性測試建構聚乙二醇人類化抗體 15-2B以增進抗體活性與治療使用性( )
|
2020/08/01 ~ 2021/07/31 |
| 14 |
109 — N 國科會(原科技部) — MOST109-2113-M-037-015 — 1 個人型
以固定酸鹼值分子動力學與體外活性實驗方法研究抗體活性具有酸鹼值依賴性之抗腫瘤壞死因子α抗體藥物Humira( )
|
2020/08/01 ~ 2021/07/31 |
| 15 |
108 — KC 高醫陽明交大 — NCTUKMU108-IF-02 —
電腦學習模擬建構pH-dependent antibody (Humira)以增進抗體再循環的使用率與治療效率( )
|
2019/08/01 ~ 2020/07/31 |
| 16 |
108 — N 國科會(原科技部) — MOST108-2113-M-037-008 — 1 個人型
以分子動力學與藥物活性實驗方法研究μ-型類鴉片受體蛋白與促進劑型胜肽之作用性( )
|
2019/08/01 ~ 2020/07/31 |
| 17 |
108 — NK 高醫-中山合作計畫 — NSYSUKMU108-I008-2 — 2 整合型
開發電腦深度學習方法應用於優化anti-PD-1 抗體-抗原結合活性與親和力( )
|
2019/01/01 ~ 2019/12/31 |
| 18 |
108 — TC 研究中心計畫 — KMU-TC108A03-1 — 6 研究中心
以電腦深度學習法客製化開發中和PD-1關鍵抗原決定位之高親和力全人類抗體藥物( )
|
2019/08/01 ~ 2020/07/31 |
| 19 |
107 — NK 高醫-中山合作計畫 — NSYSUKMU107-P005 — 1 個人型
將理論與實驗結合，利用螢光亮度高分子奈米顆粒於鑑識科學上的應用( )
|
2018/01/01 ~ 2018/12/31 |
| 20 |
107 — N 國科會(原科技部) — MOST107-2113-M-037-006 — 1 個人型
以分子動力學與藥物活性實驗方法研究μ-型類鴉片受體與胜肽之作用性(II)( )
|
2018/08/01 ~ 2019/07/31 |
| 21 |
107 — Z 大專學生研究計畫及博士後 — MOST108-2813-C-037-034-B — 8 大專學生研究計畫
108年度大專學生研究計畫-黃昱嘉(生科3)( )
|
2019/07/01 ~ 2020/02/29 |
| 22 |
106 — NK 高醫-中山合作計畫 — NSYSKMU105P017 — 1 個人型
以理論與實驗方法研究 針對 p53-dependent 癌症中 MDM2 與 MDMX 蛋白 質之雙抑制胜肽劑 質( )
|
2017/01/01 ~ 2017/12/31 |
| 23 |
106 — N 國科會(原科技部) — MOST106-2113-M-037-017 — 1 個人型
以分子動力學與藥物活性實驗方法研究μ-型類鴉片受體與胜肽之作用性( )
|
2017/08/01 ~ 2018/07/31 |
| 24 |
106 — Z 大專學生研究計畫及博士後 — MOST107-2813-C-037-013-B — 8 大專學生研究計畫
107年度大專學生研究計畫-陳奕仲(牙醫5)( )
|
2018/07/01 ~ 2019/02/28 |
| 25 |
106 — Z 大專學生研究計畫及博士後 — MOST107-2813-C-037-014-B — 8 大專學生研究計畫
107年度大專學生研究計畫-沈映成(生技3)( )
|
2018/07/01 ~ 2019/02/28 |
| 26 |
105 — NK 高醫-中山合作計畫 — — 1 個人型
將理論與實驗結合，用以合成與製作具標靶綁定特定細胞之半導體高分子奈米顆粒( )
|
2016/01/01 ~ 2016/12/31 |
| 27 |
105 — N 國科會(原科技部) — MOST105-2113-M-037-009 — 1 個人型
以分子動力學與藥物活性實驗方法研究H7N9、H1N1與H5N1之正常與突變之神經氨酸酶與環狀胜肽抑制劑之作用性( )
|
2016/08/01 ~ 2017/07/31 |
| 28 |
105 — TP 頂尖計畫(高醫) — KMU-TP105C06 —
子計畫六、利用電腦模擬及結構運算加速前驅抗體pro-Erbitux(anti-EGFR)之最佳化，以進行大腸癌專一性治療並降低副作用( )
|
2016/11/01 ~ 2017/10/31 |
| 29 |
105 — TP 頂尖計畫(高醫) — KMU-TP105C14 —
平台四、電腦模擬輔助人類化抗體與蛋白藥最佳化平台( )
|
2016/11/01 ~ 2017/10/31 |
| 30 |
104 — N 國科會(原科技部) — MOST104-2113-M-037-014 — 1 個人型
以分子動力學與藥物活性實驗方法研究H7N9/R294K突變神經氨酸酶與藥物與環狀胜肽作之作用性( )
|
2015/08/01 ~ 2016/07/31 |
| 31 |
104 — TP 頂尖計畫(高醫) — KMU-TP104C04 —
子計畫四、利用電腦模擬及結構運算加速前驅抗體pro- Erbitux (anti-EGFR)之最佳化，以進行大腸癌專一性治療並降低副作用( )
|
2015/10/01 ~ 2016/09/30 |
| 32 |
104 — TP 頂尖計畫(高醫) — KMU-TP104C08 —
平台三、電腦模擬及結構運算輔助人類化抗體與蛋白藥最佳化平台( )
|
2015/10/01 ~ 2016/09/30 |
| 33 |
104 — Z 大專學生研究計畫及博士後 — MOST105-2815-C-037-020-B — 8 大專學生研究計畫
105年度大專學生研究計畫-陳奕仲(牙醫3)( )
|
2016/07/01 ~ 2017/02/28 |
| 34 |
103 — N 國科會(原科技部) — MOST103-2113-M-037-007 — 1 個人型
以分子模擬方法研究雙抑制性胜肽藥物針對p53-dependent癌症中MDM2與MDMX蛋白抑制模型,與研究胜肽藥物形成微膠粒之機制( )
|
2014/08/01 ~ 2015/07/31 |
| 35 |
103 — TP 頂尖計畫(高醫) — KMU-TP103C10 —
Using the protease-activated pro-antibody for selective colon cancer therapy and reducing side-effects(Using the protease-activated pro-antibody for selective colon cancer therapy and reducing side-effects)
|
2014/08/01 ~ 2015/07/31 |
| 36 |
102 — N 國科會(原科技部) — NSC101-2113-M-037-011-MY2 — 1 個人型
使用量子/分子動力學方法研究新德里金屬- β-內醯胺脢1與抑制劑結合模型(2/2)( )
|
2013/08/01 ~ 2014/07/31 |
| 37 |
102 — Q 新聘教師計畫(校內) — KMU-Q103012 —
使用電腦輔助藥物設計方法研究利用生物工程改造之TMB-355(Ibalizumab)與人類CD4受體結合機制與模型( )
|
2014/01/01 ~ 2014/12/31 |